Highlights in breast cancer from ESMO 2021

Highlights from ESMO Breast Cancer 2022Подробнее

ESMO 2021 highlights in colorectal cancerПодробнее

HER2+ and TNBC highlights from ESMO 2021Подробнее

ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355Подробнее

Highlights from ESMO: DESTINY-Breast03Подробнее

Prostate and bladder highlights at ESMO 2021Подробнее

Highlights in gastric cancer from ESMO 2021Подробнее

Highlights em Câncer de Mama ASCO 2020 & ESMO Breast Cancer 2020Подробнее

Melanoma highlights from ESMO 2021Подробнее

#ESMO21 Highlights on patterns of relapse in NSCLC to atezolizumab vs BSC after adj CT: IMpower010Подробнее

#ESMO21 Highlights on pembro + chemo in 1st-line metastatic cervical cancer: The KEYNOTE-826 studyПодробнее

Highlights for skin cancer at ESMO 2021Подробнее

#ESMO21 Highlights on atezolizumab combined with FOLFOXIRI + bev in 1st-line mCRC: AtezoTRIBE studyПодробнее

ESMO 2021 RoundupПодробнее

CRC highlights from ESMO WCGIC 2021Подробнее

Breast cancer research at ESMO 2021Подробнее

Melanoma highlights from ESMO 2021Подробнее

#ESMO21 Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6Подробнее

#ESMO21 Highlights on combination of pembrolizumab plus chemotherapy in mTNBC: The KEYNOTE-355 studyПодробнее